Hyperpolarized 13C Metabolic MRI of the Human Heart
Initial Experience

Charles H. Cunningham, Justin Y.C. Lau, Albert P. Chen, Benjamin J. Geraghty, William J. Perks, Idan Roifman, Graham A. Wright, Kim A. Connelly

Rationale: Altered cardiac energetics is known to play an important role in the progression toward heart failure. A noninvasive method for imaging metabolic markers that could be used in longitudinal studies would be useful for understanding therapeutic approaches that target metabolism.

Objective: To demonstrate the first hyperpolarized 13C metabolic magnetic resonance imaging of the human heart.

Methods and Results: Four healthy subjects underwent conventional proton cardiac magnetic resonance imaging followed by 13C imaging and spectroscopic acquisition immediately after intravenous administration of a 0.1 mmol/kg dose of hyperpolarized [1-13C]pyruvate. All subjects tolerated the procedure well with no adverse effects reported ≤1 month post procedure. The [1-13C]pyruvate signal appeared within the chambers but not within the muscle. Imaging of the downstream metabolites showed 13C-bicarbonate signal mainly confined to the left ventricular myocardium, whereas the [1-13C]lactate signal appeared both within the chambers and in the myocardium. The mean 13C image signal:noise ratio was 115 for [1-13C]pyruvate, 56 for 13C-bicarbonate, and 53 for [1-13C]lactate.

Conclusions: These results represent the first 13C images of the human heart. The appearance of 13C-bicarbonate signal after administration of hyperpolarized [1-13C]pyruvate was readily detected in this healthy cohort (n=4).

This shows that assessment of pyruvate metabolism in vivo in humans is feasible using current technology.

Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02648009.

Key Words: heart failure ■ magnetic resonance imaging ■ metabolic imaging ■ metabolism ■ mitochondria

Understanding the role of altered intermediary metabolism in driving the transition from functional compensation to decompensated heart failure remains a promising avenue for the development of new therapies.1–4 The foundations of cardiac metabolism research are built on experiments in vitro and in the isolated perfused heart.5,6 However, to reproduce the effects of insulin and other hormones, plasma substrate levels, and workload/energy demand, in vivo assessment of cardiac metabolism is of paramount importance.

Editorial, see p 1146
In This Issue, see p 1145

Existing clinical imaging modalities for studying cardiac metabolism include positron emission tomography (PET) and magnetic resonance spectroscopy. Although providing unique insights into metabolism, both techniques suffer limitations. Magnetic resonance spectroscopy is only able to detect a limited range of biochemical reactions because of the inherent low sensitivity of this technique, and PET gives no information about the metabolic fate of the substrate beyond its cellular uptake. Furthermore, PET tracers deliver a dose of ionizing radiation, thus limiting repeated application. New methods for noninvasively probing the dynamics of cardiac metabolism in patients are still needed to augment the information currently available to the clinician.

Hyperpolarized carbon-13 (13C) magnetic resonance imaging (MRI) is promising in this regard because it can give images showing the uptake of metabolic substrates and subsequent intracellular conversion into downstream products.7–10 The method relies on rapid dissolution dynamic nuclear polarization, which can provide a signal enhancement of >4 orders of magnitude.7 Measurements based on these images may give new information about the metabolic state of the heart in individual patients. In addition to its scientific value as a powerful tool for investigating normal cardiac metabolism,11 developments in preclinical models support the potential clinical value of 13C MRI in evaluating pathologies.
Hyperpolarized (13)C Pyruvate Injection, was prepared using a General with padding to prevent direct contact with the transmit coil. A pulse and dextrose, to be consistent with a protocol previously established which provides automated measurement and display of release param-

Trees were recruited and gave written informed consent under a protocol approved by the Sunnybrook Research Ethics Board and approved by Health Canada as a Clinical Trial Application. Subjects were instructed to eat as they normally would, and an oral carbohydrate load was administered ≥1 hour before the pyruvate injec-
tion as 35 g of Gatorade powder in water, containing 34 g of sucrose and dextrose, to be consistent with a protocol previously established for preclinical cardiac imaging. A 20-gauge intravenous catheter was placed in the left arm before each subject was positioned supine and feet first within a 13C volume transmit coil system (GE Healthcare, Cleveland, OH) installed on a GE MR750 3.0 T MRI scanner (GE Healthcare, Waukesha, WI). The 13C receiver coil system consisted of 2 separate paddles each containing 4 receiver elements (channels). One paddle was positioned on the anterior chest wall over the heart, with the other paddle under the upper left back. The left arm was fully extended, positioned directly by the side of the subject, and supported with padding to prevent direct contact with the transmit coil. A pulse oximeter was placed on the left index finger for cardiac triggering. The investigational product, designated with the generic name Hyperpolarized (13)C Pyruvate Injection, was prepared using a General Electric SPINLab system equipped with the quality control module, which provides automated measurement and display of release param-

The 4 subjects recruited were male with no known cardiac his-
tory. Their mean age was 41 years (range 28–48). The mean LV ejection fraction was 61% (range 55%–66%). The LV end-diastolic and end-systolic volumes indexed to body surface area were 104 (range 82–115) and 41 (range 30–51) mL/m2 respectively. The mean LV mass (indexed to body surface area) was 84 g/m2 (range 62–93; Table). Of the 4 doses injected, the mean polarization was 28% (range 17%–35%), pH was 7.35 (range 7.3–7.4), temperature was 36.4°C (range 36.0–37.0°C). The duration from dissolution to the start of imaging ranged from 66 to 71 s. Imaging scan duration ranged from 14 to 21 s. The injected volume of [1-13]Cpyruvate ranged from 29 to 37 mL to achieve 0.1 mmol/kg dose.

All subjects tolerated the procedure well. Two subjects noted a sweet taste after [1-13C]pyruvate injection, which dissipated shortly afterward. No serious adverse effects were noted. During injection, there was no change in heart rate and no reported change in respiration. Noninvasive blood pressure measured before the CMR examination and

Nonstandard Abbreviations and Acronyms

CMR cardiac magnetic resonance
LV left ventricle
MRI magnetic resonance imaging
PDC pyruvate dehydrogenase complex
SNR signal-to-noise ratio

of the human heart, including myocardial viability after acute ischemia/reperfusion injury,12 early- and late-onset metabolic changes in the failing heart,13 and diabetic cardiomyopathy.14

Using the substrate [1-13C]pyruvate, which is an important intermediate of cellular metabolism, this study demonstrates the feasibility of observing, in a single examination, the following 4 different single-step enzyme-catalyzed reactions: pyruvate dehydrogenase complex (PDC), alanine aminotransferase, lactate dehydrogenase, and carbonic anhydrase. Of particular interest is the 13C-bicarbonate signal that can be measured within the myo-
cardium after an intravenous injection of [1-13C]pyruvate, which is proportional to flux of pyruvate through PDC on the mito-
ochondrial membrane.8 Because 13C MRI can be integrated into a conventional cardiovascular magnetic resonance (CMR) workup with only a small addition to the scan duration (eg, 10 minutes), the translation of this new form of MRI to patient studies is readily achievable, particularly where cardiac MRI is already used clinically. The first images of hyperpolarized 13C MRI in the hu-
man heart are presented in this pilot study in 4 healthy volunteers.

Methods

Healthy subjects (n=4) were recruited and gave written informed consent under a protocol approved by the Sunnybrook Research Ethics Board and approved by Health Canada as a Clinical Trial Application. Subjects were instructed to eat as they normally would, and an oral carbohydrate load was administered ≥1 hour before the pyruvate injection as 35 g of Gatorade powder in water, containing 34 g of sucrose and dextrose, to be consistent with a protocol previously established for preclinical cardiac imaging. A 20-gauge intravenous catheter was placed in the left arm before each subject was positioned supine and feet first within a 13C volume transmit coil system (GE Healthcare, Cleveland, OH) installed on a GE MR750 3.0 T MRI scanner (GE Healthcare, Waukesha, WI). The 13C receiver coil system consisted of 2 separate paddles each containing 4 receiver elements (channels). One paddle was positioned on the anterior chest wall over the heart, with the other paddle under the upper left back. The left arm was fully extended, positioned directly by the side of the subject, and supported with padding to prevent direct contact with the transmit coil. A pulse oximeter was placed on the left index finger for cardiac triggering. The investigational product, designated with the generic name Hyperpolarized (13)C Pyruvate Injection, was prepared using a General Electric SPINLab system equipped with the quality control module, which provides automated measurement and display of release param-

The 4 subjects recruited were male with no known cardiac his-
tory. Their mean age was 41 years (range 28–48). The mean LV ejection fraction was 61% (range 55%–66%). The LV end-diastolic and end-systolic volumes indexed to body surface area were 104 (range 82–115) and 41 (range 30–51) mL/m2 respectively. The mean LV mass (indexed to body surface area) was 84 g/m2 (range 62–93; Table). Of the 4 doses injected, the mean polarization was 28% (range 17%–35%), pH was 7.35 (range 7.3–7.4), temperature was 36.4°C (range 36.0–37.0°C). The duration from dissolution to the start of imaging ranged from 66 to 71 s. Imaging scan duration ranged from 14 to 21 s. The injected volume of [1-13]Cpyruvate ranged from 29 to 37 mL to achieve 0.1 mmol/kg dose.

All subjects tolerated the procedure well. Two subjects noted a sweet taste after [1-13C]pyruvate injection, which dissipated shortly afterward. No serious adverse effects were noted. During injection, there was no change in heart rate and no reported change in respiration. Noninvasive blood pressure measured before the CMR examination and
post [1-13C]pyruvate injection did not vary significantly. No subject reported any adverse effects ≤1 month post [1-13C]pyruvate injection. For subject 04, the 13C imaging acquisition failed because of a scanner malfunction, but the subsequent 13C spectroscopy acquisition was successful.

Table. Subject Characteristics and Scan Details

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>01</th>
<th>02</th>
<th>03</th>
<th>04</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>28</td>
<td>47</td>
<td>48</td>
<td>41</td>
<td>41</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>64</td>
<td>66</td>
<td>58</td>
<td>55</td>
<td>61</td>
</tr>
<tr>
<td>Body surface area (BSA)</td>
<td>1.79</td>
<td>1.95</td>
<td>2.12</td>
<td>1.95</td>
<td>1.95</td>
</tr>
<tr>
<td>Left ventricular (LV) mass, g/m²</td>
<td>62</td>
<td>93</td>
<td>89</td>
<td>92</td>
<td>84</td>
</tr>
<tr>
<td>LV end-diastolic volume index, mL/m²</td>
<td>82</td>
<td>107</td>
<td>110</td>
<td>115</td>
<td>104</td>
</tr>
<tr>
<td>LV end-systolic volume index, mL/m²</td>
<td>30</td>
<td>36</td>
<td>46</td>
<td>51</td>
<td>41</td>
</tr>
<tr>
<td>LV stroke volume index, mL/m²</td>
<td>52</td>
<td>70</td>
<td>64</td>
<td>64</td>
<td>63</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>69</td>
<td>57</td>
<td>55</td>
<td>47</td>
<td>57</td>
</tr>
<tr>
<td>Dose given, mL</td>
<td>29.3</td>
<td>33.0</td>
<td>37.0</td>
<td>33.0</td>
<td>33.1</td>
</tr>
<tr>
<td>Start of injection from dissolution, s</td>
<td>66</td>
<td>71</td>
<td>66</td>
<td>66</td>
<td>67</td>
</tr>
<tr>
<td>Start of scan from dissolution, s</td>
<td>77</td>
<td>84</td>
<td>95</td>
<td>82</td>
<td>85</td>
</tr>
<tr>
<td>Duration of imaging scan, s</td>
<td>14</td>
<td>17</td>
<td>19</td>
<td>21</td>
<td>18</td>
</tr>
<tr>
<td>Start of spectroscopy from dissolution, s</td>
<td>100</td>
<td>123</td>
<td>139</td>
<td>132</td>
<td>124</td>
</tr>
</tbody>
</table>

Figure 1 shows time-integrated [1-13C]pyruvate, 13C-bicarbonate and [1-13C]lactate images from 2 of the 3 normal healthy volunteers with successful imaging acquisitions. These images were reconstructed from only the 4 channels on the anterior chest wall because the posterior channels gave insignificant signal. From the spatial distributions observed in the metabolite images, the 13C-bicarbonate signal appeared mainly confined to the LV myocardium, whereas the [1-13C]pyruvate appeared within the chambers (in the blood pool) but not within the muscle. In contrast, the [1-13C]lactate signal appeared both within the chambers and in the myocardium.

The maximum image signal:noise ratio (SNR) for each 13C-labeled metabolite across the subjects is plotted in Figure 2. This was calculated as the maximum pixel value for the corresponding metabolite image divided by the SD of the noise in the image background and serves as a benchmark for the image SNR that can be obtained in humans for this particular spatial resolution and at the polarization achievable currently. However, as the SNR in MRI varies linearly with the voxel volume (holding other parameters equal), this benchmark will be useful for the design of future experiments in patients. The modest spatial resolution used here (8.8×8.8 mm in-plane and 10 mm through plane) resulted in readily detectable metabolic conversion within the tissue and enabled observations about the spatial distribution...
of the substrate and products. The bicarbonate signal:noise in the right ventricular myocardium was insufficient for reliable assessment with the chosen spatial resolution and coil configuration.

Representative dynamic $^{13}$C spectra from one of the subjects are shown in Figure 3. Despite starting the spectroscopic acquisition after the completion of $^{13}$C imaging (and at least 90 s after dissolution), major metabolites from $[1-^{13}$C]pyruvate were all observed in the spectra (Figure 3A and 3B). The peaks observed correspond to $[1-^{13}$C]lactate (185 ppm), $[1-^{13}$C]alanine (179 ppm), $[1-^{13}$C]pyruvate (172 ppm), and $^{13}$C-bicarbonate (162 ppm). From one of the data sets using the nonselective radiofrequency pulse, $^{13}$CO$_2$ was also observed, and the pH calculated from the $^{13}$C-bicarbonate and $^{13}$CO$_2$ signals using the Henderson–Hasselbalch equation was 7.1. For 3 subjects with cardiac-gated spectroscopic acquisitions, the bicarbonate:pyruvate ratios remained relatively stable during the time points with sufficient SNR for quantification, ranging from 20 to 70 s. In contrast, the lactate:pyruvate ratio increased over a similar time frame for all subjects (Figure 3C and 3D).

**Discussion**

To the best of the authors’ knowledge, these results represent the first hyperpolarized $^{13}$C images of the human heart. $[1-^{13}$C]pyruvate metabolism in the LV myocardium, as indicated by the generation of the $^{13}$C-bicarbonate signal was readily detected in this healthy cohort. This suggests that this technology may one day allow a direct measure of flux through the PDC in the myocardium in vivo in humans. The opposing patterns observed in Figure 1 for the $[1-^{13}$C]pyruvate substrate and the $^{13}$C-bicarbonate product are consistent with rapid $[1-^{13}$C]pyruvate flux through the LV myocardial PDC (consuming the $[1-^{13}$C]pyruvate in the muscle). The diffuse appearance of the $[1-^{13}$C]lactate signal was consistent with previous data from a porcine model, where the $[1-^{13}$C]lactate signal seemed diffuse in both the blood and the tissue before ischemia.$^{12}$ Understanding the more diffuse appearance of the $[1-^{13}$C]lactate signal would require further experiments, but it is clear that the largest component is in the blood pool (at the time points imaged here) and that any interpretation of whole-heart $^{13}$C spectra must take this into account.

Rationalization of the temporal evolution of the lactate:pyruvate and bicarbonate:pyruvate ratios observed in Figure 3C and 3D requires some degree of speculation. These data were acquired $\approx$1 minute after the initial bolus, so the spatial distribution of metabolites seen in Figure 1 had likely changed. A steady state was not observed for the lactate:pyruvate ratio, perhaps as a result of lactate dehydrogenase–mediated label exchange between the $^{13}$C-enriched pyruvate pool and the larger pre-existing lactate pool,$^{18}$ resulting in the $[1-^{13}$C]lactate:$[1-^{13}$C]pyruvate ratio continuing to approach the endogenous lactate:pyruvate ratio. Unlike the reversible label exchange between pyruvate and lactate, the labeling of $^{13}$C-bicarbonate is the result of an irreversible forward flux, resulting in enrichment of $^{13}$CO$_2$ and $^{13}$C-bicarbonate. Through the normal physiology of aerobic respiration, intracellular $^{13}$CO$_2$ is continually exported and transported away via the blood, draining the $^{13}$C-bicarbonate pool. This negative feedback on the $^{13}$C-bicarbonate pool may account for the more stable trend in the $^{13}$C-bicarbonate:$[1-^{13}$C]pyruvate ratio over this time frame.

Importantly, no adverse events were recorded (except for the taste experienced by 2 subjects), and the injection and $^{13}$C
imaging were well tolerated. With this tool to assess in vivo PDC flux in a rapid, safe and well-tolerated manner, longitudinal studies in humans incorporating this metabolic assessment of the heart become feasible. The metabolic information comes along with the detailed assessment of cardiac structure and function from the conventional CMR assessment done during the same scanning session. This augmented form of CMR is anticipated to provide novel insights into how metabolic changes relate to the process of functional decompensation leading to heart failure.

There are several limitations to the current technique and to this study. To apply this method, specialized equipment in the form of the SPINLab and 13C cardiac coils are required, limiting the number of sites that are currently able to do these studies. With the current polarization level and imaging method, spatial resolution was limited because of a trade-off with SNR (these will certainly improve in the future as polarization levels increase and coils are improved). Thus, imaging the ischemic heart to assess myocardial viability, or other structures in the heart, such as the right ventricle, remain technically challenging. Finally, this study only included normal volunteers, so the feasibility in a population with disease remains to be shown.

The clinical potential for this technique remains considerable. As demonstrated by our previous work in porcine models of heart failure,12 as well as work by other groups,19 the ability to perform repeated assessments of PDC flux will provide important insights into disease pathogenesis that can potentially facilitate treatment strategies in the form of PDC modulators. A significant body of work implicates PDC activity as an important determinant of cardiac function, particularly in states where insulin resistance occurs.20 For instance, in insulin-resistant ob/ob mice, enhanced fatty acid metabolism at the expense of glucose oxidation is associated with impaired contractile function.21 Indeed, there is a growing body of evidence to suggest that improving contractile function may be associated with the normalization of PDC flux. Changes in PDC activity may not only be a marker for abnormal cellular metabolism and increased oxidative stress it may also serve as a therapeutic target to prevent the development of heart failure in states where PDC activity is impaired.22 However, as the relative utilization of fatty acids and carbohydrates shifts depending on the pathogenesis and stage of disease,3 the appropriate therapy will require individualization for the particular patient, and this is where CMR plus 13C MRI may be clinically valuable.

**Conclusions**

These results represent the first 13C images of the human heart. The appearance of hyperpolarized signals of both 13CO2 and 13C-bicarbonate from [1-13C]pyruvate suggests that
this technology may one day allow a direct measure of flux through the PDC in the myocardium in vivo in humans.

Acknowledgments
We thank Tracey Rideout, Sergio DeFigueiredo, and Stephanie Vidotto for pharmacy technician support for this study, Julie Green for coordinating the study, and Ruby Endre and Garry Detzler for MR technician support.

Sources of Funding
This study was supported by the Heart and Stroke Foundation of Canada and Canadian Institutes of Health Research MOP133-504. K.A. Connelly is supported by a CIHR New Investigator award.

Disclosures
A.P. Chen is an employee of GE Healthcare. The other authors report no conflicts.

References
Hyperpolarized $^{13}$C Metabolic MRI of the Human Heart: Initial Experience
Charles H. Cunningham, Justin Y.C. Lau, Albert P. Chen, Benjamin J. Geraghty, William J. Perks, Idan Roifman, Graham A. Wright and Kim A. Connelly

_Circ Res._ 2016;119:1177-1182; originally published online September 15, 2016; doi: 10.1161/CIRCRESAHA.116.309769

_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/119/11/1177
Free via Open Access

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:
http://circres.ahajournals.org//subscriptions/